In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Purpose: KRAS mutations occur in approximately 25% of patients with non–small cell lung
cancer (NSCLC). Despite the uniform presence of KRAS mutations, patients with KRAS …

Importance There are no specifically approved targeted therapies for the most common
genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung …

Purpose: Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow
noninvasive assessment of tumor biology, yet many existing assays are cumbersome and …

Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer
(NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

ABSTRACT KRAS mutations in non-small-cell lung cancer (NSCLC) are associated with
poor prognosis. Trametinib, a selective inhibitor of MEK1/MEK2, demonstrated similar …

Introduction Mutations in the KRAS gene are the most common driver oncogenes present in
lung adenocarcinomas. We analyzed the largest multi-institutional database available …

Introduction Exon 20 insertions are the third most common family of epidermal growth factor
receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known …